EE200100187A - Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga - Google Patents

Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga

Info

Publication number
EE200100187A
EE200100187A EEP200100187A EEP200100187A EE200100187A EE 200100187 A EE200100187 A EE 200100187A EE P200100187 A EEP200100187 A EE P200100187A EE P200100187 A EEP200100187 A EE P200100187A EE 200100187 A EE200100187 A EE 200100187A
Authority
EE
Estonia
Prior art keywords
acetyldinaline
capecitabine
gemcitabine
cisplatin
combination
Prior art date
Application number
EEP200100187A
Other languages
English (en)
Estonian (et)
Inventor
Richard Grove William
Daniel Klohs Wayne
Lynn Merriman Ronald
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE200100187A publication Critical patent/EE200100187A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EEP200100187A 1998-09-25 1999-07-08 Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga EE200100187A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25
PCT/US1999/015386 WO2000018393A1 (en) 1998-09-25 1999-07-08 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin

Publications (1)

Publication Number Publication Date
EE200100187A true EE200100187A (et) 2002-08-15

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100187A EE200100187A (et) 1998-09-25 1999-07-08 Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga

Country Status (34)

Country Link
US (3) US6469058B1 (es)
EP (1) EP1115391B1 (es)
JP (1) JP2002525320A (es)
KR (1) KR20010075348A (es)
CN (1) CN1319009A (es)
AP (1) AP2001002109A0 (es)
AT (1) ATE225655T1 (es)
AU (1) AU762079B2 (es)
BG (1) BG105470A (es)
BR (1) BR9913952A (es)
CA (1) CA2342981A1 (es)
CZ (1) CZ2001905A3 (es)
DE (1) DE69903458T2 (es)
DK (1) DK1115391T3 (es)
EA (1) EA200100369A1 (es)
EE (1) EE200100187A (es)
ES (1) ES2185378T3 (es)
GE (1) GEP20043199B (es)
HK (1) HK1040190A1 (es)
HR (1) HRP20010225B1 (es)
HU (1) HUP0103640A3 (es)
ID (1) ID30046A (es)
IL (1) IL141951A0 (es)
IS (1) IS5888A (es)
NO (1) NO20011493L (es)
NZ (1) NZ510504A (es)
OA (1) OA11659A (es)
PL (1) PL348673A1 (es)
PT (1) PT1115391E (es)
SK (1) SK3602001A3 (es)
TR (1) TR200100859T2 (es)
WO (1) WO2000018393A1 (es)
YU (1) YU22401A (es)
ZA (1) ZA200102233B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU22401A (sh) * 1998-09-25 2004-03-12 Warner-Lambert Company Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
NZ550185A (en) * 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US8394757B2 (en) * 2002-10-24 2013-03-12 Spectrum Pharmaceuticals, Inc. Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
MXPA05003431A (es) * 2002-11-15 2005-07-05 Warner Lambert Co Quimioterapia de combinacion.
RU2240117C1 (ru) * 2003-04-01 2004-11-20 Алтайский государственный медицинский университет Способ лечения больных с местнораспространенными формами плоскоклеточного рака с локализацией в области слизистой оболочки полости рта и ротового отдела глотки
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
US7609809B2 (en) 2005-07-22 2009-10-27 Tomo Therapy Incorporated System and method of generating contour structures using a dose volume histogram
US7839972B2 (en) 2005-07-22 2010-11-23 Tomotherapy Incorporated System and method of evaluating dose delivered by a radiation therapy system
AU2006272742A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of delivering radiation therapy to a moving region of interest
JP2009502255A (ja) * 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 治療プランのデリバリにおける品質保証基準を評価するための方法およびシステム
WO2007014093A2 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for processing data relating to a radiation therapy treatment plan
KR20080039916A (ko) 2005-07-22 2008-05-07 토모테라피 인코포레이티드 움직이는 관심 영역에 방사선 치료를 시행하는 시스템 및방법
EP1907058B1 (en) 2005-07-22 2015-06-24 TomoTherapy, Inc. Method of placing constraints on a deformation map and system for implementing same
CA2616316A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for adapting a radiation therapy treatment plan based on a biological model
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
CA2616309A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated Method of and system for predicting dose delivery
JP2009502257A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド デリバーされた線量を評価するための方法およびシステム
KR20080044250A (ko) 2005-07-23 2008-05-20 토모테라피 인코포레이티드 갠트리 및 진료대의 조합된 움직임을 이용하는 방사선치료의 영상화 및 시행
EP2236145B1 (en) * 2008-01-28 2014-05-14 NanoCarrier Co., Ltd. Pharmaceutical composition and combined agent
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
EP2417146B1 (en) 2009-04-06 2016-07-13 Otsuka Pharmaceutical Co., Ltd. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one derivatives for treating cancer
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US8691875B2 (en) 2011-07-01 2014-04-08 Broad Institute, Inc. Solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
WO2014133849A2 (en) 2013-02-26 2014-09-04 Accuray Incorporated Electromagnetically actuated multi-leaf collimator
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
WO2020028392A1 (en) 2018-07-30 2020-02-06 Duke University Niclosamide analogues and therapeutic use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
WO1998047500A1 (en) 1997-04-24 1998-10-29 Warner-Lambert Company Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
YU22401A (sh) * 1998-09-25 2004-03-12 Warner-Lambert Company Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom

Also Published As

Publication number Publication date
GEP20043199B (en) 2004-03-25
SK3602001A3 (en) 2002-07-02
ID30046A (id) 2001-11-01
YU22401A (sh) 2004-03-12
ATE225655T1 (de) 2002-10-15
CZ2001905A3 (cs) 2001-08-15
US6469058B1 (en) 2002-10-22
AU762079B2 (en) 2003-06-19
CA2342981A1 (en) 2000-04-06
DE69903458T2 (de) 2003-07-10
PT1115391E (pt) 2003-02-28
AU5092199A (en) 2000-04-17
CN1319009A (zh) 2001-10-24
AP2001002109A0 (en) 2001-03-31
PL348673A1 (en) 2002-06-03
NO20011493D0 (no) 2001-03-23
US20030170300A1 (en) 2003-09-11
BR9913952A (pt) 2001-06-12
TR200100859T2 (tr) 2001-08-21
WO2000018393A1 (en) 2000-04-06
EP1115391B1 (en) 2002-10-09
BG105470A (en) 2001-12-29
HUP0103640A2 (en) 2002-06-29
US20030086965A1 (en) 2003-05-08
JP2002525320A (ja) 2002-08-13
KR20010075348A (ko) 2001-08-09
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
IS5888A (is) 2001-03-14
EA200100369A1 (ru) 2001-10-22
HK1040190A1 (zh) 2002-05-31
NZ510504A (en) 2003-09-26
ZA200102233B (en) 2002-06-18
EP1115391A1 (en) 2001-07-18
ES2185378T3 (es) 2003-04-16
NO20011493L (no) 2001-05-23
HRP20010225B1 (en) 2004-10-31
HRP20010225A2 (en) 2002-04-30
DK1115391T3 (da) 2003-02-10
OA11659A (en) 2004-12-08
DE69903458D1 (de) 2002-11-14

Similar Documents

Publication Publication Date Title
HUP0103640A3 (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
EE200000577A (et) Elektronpääsmete või nendega seotud täiustused
PT1114031E (pt) 4-carboxiamino-1,2,3,4-tetradhiroquinolinas substituidas em posicao 2
NO20006520L (no) Adenosinderivater
ID27433A (id) Deret transmit pancaran ganda dengan intermodulasi rendah
BR9912040B1 (pt) vÁlvula em profundidade, e acabamento de poÇo.
NO20013099D0 (no) Kombinasjonskjemoterapi
ZA992255B (en) Antitumor synergetic composition.
ZA200201548B (en) Parenteral cisplatin emulsion.
TR199900635A3 (tr) Pozitif kontrollü tüylendirme silindirleri içeren tüylendirme makinesi.
SI1115391T1 (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
FR2779658B1 (fr) Planche de glisse
NO985156D0 (no) Vinkeldeling
IT1305654B1 (it) Resistenze corazzate con guaina perfezionata.
ES1039380Y (es) Pendiente de cierre delantero.
KR980000233U (ko) 주머니를 구비한 장갑
DK9800114U3 (da) Jalousi-skab med oplukkelig bordarr. med integreret opslagstavle
ES1040517Y (es) Sembradora de semillas en bandejas.
BR8101034Y1 (pt) disposição introduzida em luminária de embutir.
ES1041848Y (es) Perfil frontal para cerraduras.
IT1304980B1 (it) Registro bidirezionale per porte,specialmente per porte blindate.
SK2354U (sk) Dvere s požiarnou odolnosťou 30 minút, bezpečnostné-nepriestrelné
BR8202541Y1 (pt) aperfeiçoamento introduzido em bolsão.
ES1042631Y (es) Banco continuo ondulado-circular, con respaldo ergonomico.
ES1041380Y (es) Puerta acorazada perfeccionada.